Geneva, Switzerland, 16 July 2025 – 8:00 am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that the Lyon Economic Activities Court has pronounced on July 15, 2025, the liquidation of GeNeuro Innovation SAS, the sole subsidiary of GeNeuro SA.
This decision follows the opening on June 11, 2025, of receivership proceedings for GeNeuro Innovation SAS. The Court appointed SELARL MJ-Synergie as liquidator. This is part of the restructuring process of the GeNeuro Group, which announced on May 27 that it had obtained a definitive debt-restructuring moratorium until September 28, 2025, in Switzerland for its parent company, GeNeuro SA, a moratorium which is not affected by the receivership of its subsidiary.
About GeNeuro
- GeNeuro‘s mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA. GeNeuro is based in Geneva, Switzerland.
- For more information, visit: www.geneuro.com